理解市场 | 康方生物涨近 5% 再创新高 依沃西联合方案治疗 IO 耐药 NSCLC 三期临床完成首例给药
AKESO's stock price rose nearly 5% in the morning session, reaching a new high of HKD 160.4, currently reported at HKD 158.7, with a transaction volume of HKD 950 million. The company announced that the Phase III clinical study of its PD-1/VEGF bispecific antibody new drug, Ivosidenib combined with Docetaxel, has completed its first administration, marking the initiation of the 7th Phase III study in the field of lung cancer. Ivosidenib is expected to reshape the treatment landscape for advanced non-small cell lung cancer
According to Zhitong Finance APP, Akeso (09926) rose nearly 5% in the morning session, reaching a high of HKD 160.4, setting a new historical high. As of the time of publication, it was up 3.86%, trading at HKD 158.7, with a transaction volume of HKD 950 million.
In terms of news, Akeso announced that its independently developed globally first PD-1/VEGF bispecific antibody new drug Ivosidenib (trade name: YidaFang®) in combination with Docetaxel, for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that has failed PD-1/L1 inhibitors and platinum-based chemotherapy, has completed the first patient dosing in the registrational Phase III clinical study (AK112-305/HARMONi-8A).
It is noteworthy that this is the 7th Phase III study of Ivosidenib in the field of lung cancer (three of which are international multicenter registrational clinical trials). As a globally pioneering PD-1/VEGF bispecific antibody, Ivosidenib has achieved comprehensive coverage of core indications in the NSCLC field, completing the layout for multi-line treatment, and is expected to reshape the overall treatment landscape for advanced NSCLC globally. Meanwhile, Ivosidenib, as the cornerstone drug of the company's "IO+ADC" 2.0 strategy, has already initiated a series of Phase III and Phase II clinical trials targeting core indications for tumor immunotherapy in first-line treatment
